Literature DB >> 15990965

Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.

Munetaka Takekuma1, Makoto Maeda, Takachika Ozawa, Kazuhiko Yasumi, Tatsuo Torizuka.   

Abstract

BACKGROUND: Recurrent ovarian cancer is refractory and resistant to treatment in most patients, and no effective treatment for it has been established. Starting a treatment when tumors still consist of micro foci may contribute to improvement of prognosis. Therefore, the early diagnosis of relapse is important.
METHODS: Among patients with epithelial ovarian cancer in whom initial treatment achieved remission between April 1998 and December 2003, those patients in whom the cancer-related antigen (CA)125 level was increased during the subsequent follow-up period, or those who showed abnormal computed tomography (CT)/magnetic resonance imaging (MRI) findings despite normal CA125 levels, were examined by 18F-fluoro-2-deoxyglucose - positron emission tomography (FDG-PET). We compared the rates of accurate diagnosis of recurrence achieved using CT/MRI, CA125, and FDG-PET in patients with a definitive diagnosis of relapse.
RESULTS: We investigated 29 patients with epithelial ovarian cancer. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of FDG-PET were 84.6% (22/26), 100% (3/3), 100% (22/22), 42.9% (3/7), and 86.2% (25/29), respectively. These values were higher than the corresponding values obtained using CT/MRI or CA125 levels.
CONCLUSION: FDG-PET may be very useful for identifying sites of recurrent ovarian cancer, although this procedure had a low NPV because of the high rate of false-negative findings for micro or cystic lesions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15990965     DOI: 10.1007/s10147-005-0489-6

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  22 in total

1.  The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.

Authors:  S M Eisenkop; R L Friedman; N M Spirtos
Journal:  Cancer       Date:  2000-01-01       Impact factor: 6.860

2.  Second-look laparotomy and salvage therapy: a research modality only?

Authors:  M E Potter; K D Hatch; S J Soong; E E Partridge; J M Austin; H M Shingleton
Journal:  Gynecol Oncol       Date:  1992-01       Impact factor: 5.482

3.  Second thoughts about second-look laparotomy in advanced ovarian cancer.

Authors:  J B Friedman; N S Weiss
Journal:  N Engl J Med       Date:  1990-04-12       Impact factor: 91.245

4.  A second look at second-look laparotomy.

Authors:  R C Young
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

5.  Evaluation of the role of second-look surgery in ovarian cancer.

Authors:  S K Chambers; J T Chambers; E I Kohorn; R Lawrence; P E Schwartz
Journal:  Obstet Gynecol       Date:  1988-09       Impact factor: 7.661

6.  Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?

Authors:  B Patsner; J W Orr; W J Mann; P T Taylor; E Partridge; T Allmen
Journal:  Gynecol Oncol       Date:  1990-09       Impact factor: 5.482

7.  [The value of preoperative diagnosis before second-look laparotomy in ovarian cancer].

Authors:  H Meden; W Rath; D Ohlmeyer
Journal:  Geburtshilfe Frauenheilkd       Date:  1990-02       Impact factor: 2.915

8.  Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.

Authors:  Tatsuo Torizuka; Shuji Nobezawa; Toshihiko Kanno; Masami Futatsubashi; Etsuji Yoshikawa; Hiroyuki Okada; Munetaka Takekuma; Makoto Maeda; Yasuomi Ouchi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03-19       Impact factor: 9.236

9.  Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.

Authors:  M Markman; M F Brady; N M Spirtos; P Hanjani; S C Rubin
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

10.  Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma.

Authors:  B Y Karlan; R Hawkins; C Hoh; M Lee; N Tse; P Cane; J Glaspy
Journal:  Gynecol Oncol       Date:  1993-11       Impact factor: 5.482

View more
  12 in total

1.  Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.

Authors:  Yukihiro Hama
Journal:  Int J Clin Oncol       Date:  2006-06       Impact factor: 3.402

2.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

3.  Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.

Authors:  Federico Caobelli; Pierpaolo Alongi; Laura Evangelista; Maria Picchio; Giorgio Saladini; Marco Rensi; Onelio Geatti; Angelo Castello; Iashar Laghai; Cristina E Popescu; Carlotta Dolci; Cinzia Crivellaro; Silvia Seghezzi; Margarita Kirienko; Vincenzo De Biasi; Fabrizio Cocciolillo; Natale Quartuccio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-18       Impact factor: 9.236

4.  18F-FDG PET/CT evaluation of patients with ovarian carcinoma.

Authors:  Andrei H Iagaru; Erik S Mittra; Iain Ross McDougall; Andrew Quon; Sanjiv Sam Gambhir
Journal:  Nucl Med Commun       Date:  2008-12       Impact factor: 1.690

5.  [(18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results.

Authors:  Karsten Beiderwellen; Johannes Grueneisen; Verena Ruhlmann; Paul Buderath; Bahriye Aktas; Philipp Heusch; Oliver Kraff; Michael Forsting; Thomas C Lauenstein; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09-16       Impact factor: 9.236

6.  Metabolomic Characterization of Ovarian Epithelial Carcinomas by HRMAS-NMR Spectroscopy.

Authors:  D Ben Sellem; K Elbayed; A Neuville; F-M Moussallieh; G Lang-Averous; M Piotto; J-P Bellocq; I J Namer
Journal:  J Oncol       Date:  2011-04-26       Impact factor: 4.375

7.  Long Term Prognostic Implications of Expression of Glucose Transporter-1 and Hexokinase II in Patients with Stage I Uterine Leiomyosarcoma.

Authors:  Hitomi Tsukada; Toshinari Muramatsu; Masaki Miyazawa; Tetsuji Iida; Masae Ikeda; Masako Shida; Takeshi Hirasawa; Hiroshi Kajiwara; Masaru Murakami; Masanori Yasuda; Mikio Mikami
Journal:  Acta Histochem Cytochem       Date:  2012-04-21       Impact factor: 1.938

8.  Appropriateness criteria of FDG PET/CT in oncology.

Authors:  Archi Agrawal; Venkatesh Rangarajan
Journal:  Indian J Radiol Imaging       Date:  2015 Apr-Jun

9.  Pelvic exenteration case series: A single surgeon's experience at one institution in Trinidad and Tobago.

Authors:  Ravi Maharaj; Vandana Devika Sookdeo; Maurice Fortuné; Meenakshi Akhilesh; Chalapathi Rao Adidam Venkata; Wayne Mohammed; Dave Harnanan; Wayne A Warner
Journal:  Int J Surg Case Rep       Date:  2017-03-07

Review 10.  Diagnostic role of 18F-FDG PET/MRI in patients with gynecological malignancies of the pelvis: A systematic review and meta-analysis.

Authors:  Ji Nie; Jing Zhang; Jinsheng Gao; Linghong Guo; Hui Zhou; Yuanyuan Hu; Chenjing Zhu; Qingfang Li; Xuelei Ma
Journal:  PLoS One       Date:  2017-05-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.